Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Below CrCl 30 mL/min, the fixed combination cannot deliver the necessary lamivudine adjustment. Use individually dosed components when adjustment is required. Limits and monitoring Select the correct adult or pediatric presentation. Monitor for lamivudine toxicity at sustained CrCl 30-49 mL/min. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 30, posted Jan 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently. Limits and monitoring Use individually selected components if renal adjustment is necessary. Verify all active ingredients. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 2, posted Apr 28, 2014 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment does not require an automatic abaloparatide dose reduction. Severe impairment increases exposure and warrants monitoring for adverse reactions. Limits and monitoring Assess tolerance and calcium-related adverse effects. No dialysis schedule is established here. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 19, posted Aug 17, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prescribing information does not call for a renal dose reduction for this inhaled maintenance product. Limits and monitoring Verify the inhaler, active ingredients and indication. The renal guidance does not supply dialysis timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Dec 08, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Use alfuzosin ER cautiously below CrCl 30 mL/min. Severe impairment contributed only six patients to the cited safety experience. Limits and monitoring Systemic exposure increased in renal impairment. No numerical renal dose reduction is specified here. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Jan 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate impairment requires no alirocumab dose reduction. Severe renal impairment lacks data in the cited source. Limits and monitoring The mild/moderate conclusion does not supply a dialysis regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 35, posted Jul 24, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Aliskiren is contraindicated with an ACE inhibitor or ARB in diabetes because the combination increases the risk of kidney injury, hypotension and hyperkalemia. Limits and monitoring This is an interaction restriction. Review combined renin-angiotensin blockade, potassium, and renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Mar 12, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Use the usual renal dose at CrCl 30-90 mL/min. Safety and efficacy of the fixed combination in severe impairment remain unestablished. Limits and monitoring Consider the thiazide component and the specific restrictions on concurrent ACE inhibitors or ARBs. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Nov 17, 2022 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30 to below 60 mL/min, use alogliptin 12.5 mg/pioglitazone 30 mg once daily. The combination is not recommended below 30 or in ESRD. Limits and monitoring Use the component strengths in the order shown. Review heart failure and fluid retention before prescribing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 23, posted Mar 24, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Ambrisentan requires no renal adjustment in mild or moderate impairment. Limits and monitoring The cited recommendation does not establish a dose in severe impairment or dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 28, posted Jun 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The usual initial amlodipine dose can be used in renal failure because renal impairment has little influence on drug disposition. Limits and monitoring Titrate to blood pressure and tolerability. This finding concerns single-ingredient amlodipine. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 10, posted Dec 10, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The source describes no initial renal adjustment in moderate to marked impairment with CrCl below 40 mL/min. Limits and monitoring Check blood pressure, volume status and creatinine during titration. An initial-dose statement supplies no postdialysis instruction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Jul 13, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
